Evidence suggests that children will change their minds as they age: approximately ¾ of pre-pubescent children attending gender identity clinics will not want to change their gender once puberty starts.
Treatments for under 18 gender dysphoric children and adolescents remain largely experimental. There are a large number of unanswered questions that include the age at start, reversibility; adverse events, long term effects on mental health, quality of life, bone mineral density, osteoporosis in later life and cognition. We wonder whether off label use is appropriate and justified for drugs such as spironolactone which can cause substantial harms, including death. We are also ignorant of the long-term safety profiles of the different GAH regimens. The current evidence base does not support informed decision making and safe practice.
Source: Gender-affirming hormone in children and adolescents | BMJ EBM Spotlight